Pure Global
NCT06134622

Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT)

The First Affiliated Hospital of University of Science and Technology of China·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Ischemic Stroke
Drug/Device/Intervention
Intravenous thrombolysis plus tirofiban
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The First Affiliated Hospital of University of Science and Technology of China
Location
Hefei, China
Timeline & enrollment
Phase
Phase 3
Start date
Jan 01, 2024
End date
Jun 30, 2027
Enrollment
832 participants
Primary outcome

a modified Rankin Score of 0-1

Summary

To assess the efficacy and safety of tirofiban administration after intravenous thrombolysis
 for patients with AIS.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06134622
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06134622 through Pure Global AI's free database. This Phase 3 trial is sponsored by The First Affiliated Hospital of University of Science and Technology of China and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 832 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.